Standard Biotools Inc (OQ:LAB)

Business Focus: Advanced Medical Equipment & Technology

Apr 25, 2024 08:01 am ET
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company’s...
Apr 25, 2024 08:00 am ET
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company’s management will host a...
Apr 08, 2024 08:00 am ET
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™...
Apr 03, 2024 04:01 pm ET
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers...
Mar 18, 2024 08:12 am ET
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to...
Feb 28, 2024 04:01 pm ET
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Standard BioTools Stand-Alone 2023 Fourth Quarter and Full Year Selected...
Feb 26, 2024 08:00 am ET
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of...
Feb 22, 2024 04:05 pm ET
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences: TD Cowen’s 44th Annual...
Feb 14, 2024 08:30 am ET
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024,...
Feb 07, 2024 08:30 am ET
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Navignostics AG for development of clinical research applications and...
Jan 08, 2024 08:30 am ET
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue
Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited...
Jan 05, 2024 08:46 am ET
Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated...
Jan 04, 2024 10:23 pm ET
Standard BioTools Stockholders Approve Merger with SomaLogic
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the...
Jan 04, 2024 08:44 pm ET
SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting
Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction
Dec 29, 2023 05:04 pm ET
Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has...
Dec 28, 2023 03:16 pm ET
Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools
BOULDER, Colo., Dec. 28, 2023 /PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. ("Standard") (Nasdaq: LAB). 
Dec 26, 2023 02:59 pm ET
SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure
SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic's Thorough Strategic Process
Dec 22, 2023 06:57 pm ET
ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended...
Dec 21, 2023 08:00 am ET
SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools
SomaLogic, Inc. (Nasdaq: SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (Nasdaq: LAB) on October 4, 2023. The Company also filed an investor presentation, which can be...
Dec 20, 2023 09:00 am ET
Skye Fund III Issues Letter Regarding Opposition to SomaLogic’s Proposed Merger with Standard BioTools
Skye Fund III, which together with its affiliates, owns approximately 3.4 million shares of SomaLogic, Inc., (NASDAQ: SLGC) (the “Company”) and has been an investor in the Company for 20 years, today issued an open letter to the Company’s...
Dec 17, 2023 03:37 pm ET
Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC)
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”)...
Dec 11, 2023 10:37 am ET
Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC)
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”)...
Dec 07, 2023 11:01 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CERE, SLGC, LAB
NEW YORK, Dec. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 06, 2023 11:18 am ET
Lowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC)
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”)...
Dec 05, 2023 05:30 pm ET
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.
Dec 04, 2023 08:00 am ET
Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that the companies...
Nov 18, 2023 09:41 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JVA, SMMF, RPT, LAB
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Coffee Holding Co., Inc. (NASDAQ:...
Nov 07, 2023 04:00 pm ET
Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results
BioTools Inc. (“SBI” or the “Company”) (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the third quarter ended September 30, 2023. 2023 Selected...
Nov 02, 2023 08:30 am ET
Standard BioTools to Present at the Jefferies London Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated...
Oct 25, 2023 08:30 am ET
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of...
Oct 10, 2023 10:22 am ET
Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Oct 08, 2023 10:08 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, ORTX, LAB, SLGC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SP® Plus Corporation (NASDAQ: SP)’s...
Oct 06, 2023 02:40 pm ET
STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.
Oct 05, 2023 02:42 pm ET
Moore Kuehn Encourages APRN, FRGI, LAB, and CPRI Investors to Contact Law Firm
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Oct 04, 2023 02:17 pm ET
LAB INVESTOR ALERT: Julie & Holleman LLP Announces Investigation of Proposed Merger Between Standard BioTools and SomaLogic
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman LLP is investigating potential breaches of fiduciary duty relating to the proposed merger between Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic, Inc. (Nasdaq: SLGC).
Oct 04, 2023 02:07 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LiveVox Holdings, Inc. (Nasdaq - LVOX), Standard BioTools Inc. (Nasdaq - LAB), PFSweb, Inc. (Nasdaq – PFSW), Ho
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 04, 2023 11:56 am ET
LAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Standard BioTools Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. is fair to Standard BioTools shareholders. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company.
Oct 04, 2023 09:31 am ET
Thinking about buying stock in ShiftPixy, Polished.Com, Brooge Energy, Standard Biotools, or FingerMotion?
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIXY, POL, BROG, LAB, and FNGR.
Oct 04, 2023 08:00 am ET
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that they have entered into...
Aug 08, 2023 04:05 pm ET
Standard BioTools Reports Second Quarter 2023 Financial Results
Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the second quarter ended June 30, 2023....
Jul 26, 2023 04:05 pm ET
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Canaccord Genuity 43rd...
Jul 25, 2023 04:05 pm ET
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of...
Jun 14, 2023 07:30 am ET
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Capital One Securities 2nd...
May 25, 2023 04:05 pm ET
Standard BioTools to Present at the Jefferies Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation at the Jefferies...
May 18, 2023 07:30 am ET
Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of NGS library preparation functionality on the X9™ High-Throughput Genomics System. For the...
May 15, 2023 07:30 am ET
Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black...
May 09, 2023 04:05 pm ET
Standard BioTools Reports First Quarter 2023 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the first quarter ended March 31, 2023. “Our focus continues to be the...
Apr 25, 2023 04:30 pm ET
Standard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of the...
Apr 20, 2023 05:03 pm ET
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards, effective as of April 20, 2023, under the Standard BioTools...
Apr 17, 2023 08:30 am ET
Standard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American...
Mar 22, 2023 08:30 am ET
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools...
Mar 15, 2023 08:30 am ET
Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Fenel Eloi to its Board of Directors (“Board”). Eloi will also serve on the Board’s...
Mar 14, 2023 08:30 am ET
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at...
Mar 01, 2023 04:05 pm ET
Standard BioTools to Present at 43rd Annual Cowen Health Care Conference
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care...
Feb 21, 2023 08:30 am ET
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Standard BioTools...
Feb 14, 2023 04:05 pm ET
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the fourth quarter and year ended December 31, 2022. “I’m pleased with the results...
Jan 31, 2023 08:30 am ET
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023,...
Jan 09, 2023 08:30 am ET
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced preliminary fourth quarter and full year 2022 revenue and provided a business update. “Standard BioTools...
Jan 03, 2023 08:30 am ET
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Betsy Jensen as Chief Human Resources Officer. Jensen will lead Standard BioTools™...
Nov 28, 2022 08:30 am ET
Standard BioTools Authorizes up to $20 Million of Share Repurchases
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that its board of directors has authorized the repurchase of up to $20 million of shares of its common...
Nov 22, 2022 09:20 am ET
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022, under the Standard BioTools...
Nov 08, 2022 04:05 pm ET
Standard BioTools Announces Third Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced financial results for the third quarter ended September 30, 2022.  “While still early and just two...
Nov 07, 2022 04:05 pm ET
Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – and Visiopharm® today announced a collaboration to pair the company’s Hyperion™ and Hyperion+™ Imaging Systems with...
Oct 25, 2022 08:30 am ET
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of...
Oct 13, 2022 08:30 am ET
Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of...
Oct 06, 2022 08:30 am ET
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the launch of the X9™ Real-Time PCR System, an innovative high-capacity genomics instrument offering...
Aug 25, 2022 04:05 pm ET
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of August 22, 2022, under the Standard BioTools...
Aug 08, 2022 04:02 pm ET
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced financial results for the second quarter ended June 30, 2022.  “Four months after I joined the company...
Jul 25, 2022 04:30 pm ET
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of...
May 05, 2022 04:02 pm ET
Standard BioTools Announces First Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced financial results for the first quarter ended March 31, 2022.   “The end of first quarter 2022 marked...
Apr 22, 2022 04:02 pm ET
Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of the...
Apr 11, 2022 08:30 am ET
Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging
Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced the launch of the Hyperion+™ Imaging System, the new standard in high-plex spatial imaging, providing...
Apr 05, 2022 07:15 pm ET
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (f/k/a Fluidigm Corporation) (Nasdaq:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company’s new President, Chief...
Apr 04, 2022 05:30 pm ET
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
Fluidigm Corporation (Nasdaq:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”). Fluidigm has been...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.